A new agreement with Novo Nordisk highlights unique positioning in GLP-1 implant development, with a clinical trial for the semaglutide implant set to begin in August. The platform aims to improve adherence and outcomes through steady, long-term drug delivery.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.